Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients

• Status: Terminated
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double-blind, placebo-controlled, parallel groups study to determine whether prosptide is effective in relieving pain in patients who have sensory neuropathic pain related to their HIV infection or the drugs used to treat it.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Savient Pharmaceuticals
• Collaborator: Neurologic AIDS Research Consortium (NARC)

Criteria

Inclusion Criteria:

• Ages 18 years and older